Product Description
Product Name: Ruxolitinib Tablets
Strength: 15 mg
Form: Oral Tablet
Category: Janus Kinase (JAK) Inhibitor / Targeted Therapy
Indication: Myeloproliferative Disorders and Inflammatory Conditions
Ruxolitinib 15 mg Tablets are an oral targeted therapy classified as a Janus Kinase (JAK) inhibitor, used to treat certain blood cancers and chronic inflammatory conditions by modulating the JAK-STAT signaling pathway, which plays a key role in immune function and cell growth.
